ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

An Interventional Study Evaluating Cell Mediated Immunity to Guide Therapy for CMV Viremia.

M. Mian, A. Humar, S. Keshwani, S. Husain, P. Ashton, S. Han, L. Singer, J. Kim, E. Renner, D. Kumar.

Multi-Organ Transplant, University Health Network, Toronto, ON, Canada.

Meeting: 2016 American Transplant Congress

Abstract number: 306

Keywords: Cytomeglovirus, Infection, Interferon (IFN), T cells

Session Information

Date: Monday, June 13, 2016

Session Name: Concurrent Session: CMV: Immune Monitoring & MicroRNA Responses

Session Time: 4:30pm-6:00pm

 Presentation Time: 4:54pm-5:06pm

Location: Room 306

Related Abstracts
  • Recurrent Cytomegalovirus Infection After Solid Organ Transplant
  • Cytometric Deep Profiling of the CD8+ T-Cell Compartment in Transplant Patients with CMV Viremia.

Background

Patients treated for CMV viremia commonly relapse after discontinuation of therapy. CMV-specific CD8+ T-cell mediated immunity (CMI) is useful to predict the risk of CMV reactivation but has not been evaluated in interventional trials. We hypothesized that CMI assessment could be used to tailor therapy for CMV viremia by guiding the need for secondary prophylaxis following initial treatment.

Methods

Transplant patients were enrolled in this prospective study at the onset of CMV viremia requiring antiviral therapy (>1000 IU/mL). CMI was measured serially using the Quantiferon-CMV (QFT-CMV) assay. Patients were treated with antiviral therapy until viral load was negative. Following that, the real-time result of the QFT-CMV assay was used to guide therapy: patients with a positive CMI assay had antivirals discontinued; patients with a negative CMI had two months of secondary antiviral prophylaxis. All patients were monitored by serial CMV PCR assays. The primary endpoint was relapse defined as detectable viremia (>137 IU/ml) requiring antiviral therapy.

Results

We enrolled 21 patients (liver=4, lung=7, kidney=6, combined=4) of which 17 had sufficient follow-up for analysis. Median age was 53 years (range 29-76) and 10 patients had symptomatic CMV disease and 7 patients had asymptomatic viremia. Median viral load at onset was 10,900 IU/ml (range 1,920-1,220,000). All patients received antiviral therapy until viral load was negative. Relapse occurred in 9 patients (52.9%) at a median of 59 days (range 7-169). At end-of-treatment, 6 patients (35.3%) had a positive CMI response (median IFN-γ response to CMV=3.40 IU/mL) and discontinued antivirals. CMI was negative in 11 patients (64.7%), who therefore received 2 months of secondary prophylaxis. During the follow-up, patients with a negative CMI were still more likely to have CMV relapse compared with those who were positive [8/11 (72.7%) vs. 1/6 (16.7%), p=0.05). Hospitalization due to CMV disease tended to be lower in the CMI positive vs. CMI negative patients (0/6 (0%) vs. 5/11 (45.5%); p=0.1).

Conclusion

This study provides a first proof of concept that therapy for CMV viremia can be successfully tailored based on measurement of the CMV specific CD8+ T-cell response. This allowed minimization of antivirals in a subset of patients without adverse sequelae.

CITATION INFORMATION: Mian M, Humar A, Keshwani S, Husain S, Ashton P, Han S, Singer L, Kim J, Renner E, Kumar D. An Interventional Study Evaluating Cell Mediated Immunity to Guide Therapy for CMV Viremia. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Mian M, Humar A, Keshwani S, Husain S, Ashton P, Han S, Singer L, Kim J, Renner E, Kumar D. An Interventional Study Evaluating Cell Mediated Immunity to Guide Therapy for CMV Viremia. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/an-interventional-study-evaluating-cell-mediated-immunity-to-guide-therapy-for-cmv-viremia/. Accessed March 6, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Factors Influencing Creatinine Rise Following Donor Nephrectomy

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.